title: [Heavy legs, venous insufficiency of the legs and hormone substitution therapy].
abstract: The effects of estrogens and gestagens on veins and circulation have been studied since prescription of these hormones as oral contraception and description of related thromboembolic events. The identification of different receptors and the description of these receptors in venous walls have helped to understand some hormonal effects. However, the actual knowledge remains insufficient to explain the complexity of the actions of hormones on venous function. The distribution, the density and the receptor types vary with age, gender, hormonal status and vascular bed. Gestagens mainly reduce the tone of venous walls, whereas estrogens have various effects. Between 25% and 50% of European adults and even 80% or more in some risk groups complain about heavy legs, with or without chronic venous insufficiency. The number of women to whom hormonal substitution is or could be prescribed increases along with aging of populations and the better understanding of potential benefits. The need for a better understanding of vascular effects of sexual hormones is growing, since the incidence of chronic venous insufficiency of the legs increases with age. The life prognosis will not be affected by a deterioration of a chronic venous insufficiency. In contrast, the quality of life, morbidity and the cost of treatment will be expected to change. In addition, thromboembolic events have to be considered, as has been shown in recent studies. These findings outline the need for further studies on the relation between hormones and venous function and for some caution when prescribing hormonal substitution.
authors.affiliation: Division d'Hypertension et de Médecine Vasculaire, Centre Hospitalier Universitaire Vaudois, Lausanne.
authors.forename: E
authors.initials: E
authors.lastname: Haesler
authors.forename: D
authors.initials: D
authors.lastname: Hayoz
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000139:chemically induced* / Q000517:prevention & control; D012307:Risk Factors; D014689:Venous Insufficiency / Q000139:chemically induced* / Q000517:prevention & control; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000517:prevention & control
chemical_list: D003278:Contraceptives, Oral, Hormonal